Seminars in Oncology Nursing
Volume 25, Issue 2 , Pages 120-128 , May 2009

Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation

References 

  1. Thomas ED. Stem cell transplantation: past, present and future. Arch Immunol Ther Exp. 1997;45:1–5
  2. Banna GL, Aversa S, Sileni VC, et al. Nonmyeloablative allogeneic stem cell transplantation (NST) after truly nonmyeloablative and reduced intensity conditioning regimens. Crit Rev Oncol Hematol. 2004;51:171–189
  3. Thomas ED, Storb R, Clift RA, et al. Bone-marrow transplantation (second of two parts). N Engl J Med. 1975;292:895–902
  4. Champlin R, Khouri I, Shimoni A, et al. Harnessing graft-versus-malignancy: Non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. Br J Haematol. 2000;111:18–29
  5. Battiwalla M, Barrett J. Allogeneic transplantation using non-myeloablative transplant regimens. Best Pract Res Clin Haematol. 2001;14:701–722
  6. Childs R, Clave E, Contentin N, et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood. 1999;94:3234–3241
  7. Khan F, Agarwal A, Agrawal S. Significance of chimerism in hematopoietic stem cell transplantation: new variations on an old theme. Bone Marrow Transplant. 2004;34:1–12
  8. Loberiza F. Report on the state of the art in blood and marrow transplantation. Part 1 of the IBMTR/ABMTR summary slides with guide. IBMTR/ABMTR Newsletter. 2003;10:7–10
  9. McCann SR, Crampe M, Molloy K, et al. Hemopoietic chimerism following stem cell transplantation. Transfus Apher Sci. 2005;32:55–61
  10. Canals C, Martino R, Sureda A, et al. Strategies to reduce transplant-related mortality after allogeneic stem cell transplantation in elderly patients: comparison of reduced-intensity conditioning and unmanipulated peripheral blood stem cells vs a myeloablative regimen and CD34+ cell selection. Exp Hematol. 2003;31:1039–1043
  11. Diaconescu R, Flowers CR, Storer B, et al. Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. Blood. 2004;104:1550–1558
  12. Wong R, Shahjahan M, Wang X, et al. Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation. Biol Blood Marrow Transplant. 2005;11:108–114
  13. Sorror ML, Maris MB, Storer B, et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. Blood. 2004;104:961–968
  14. Maruyama D, Fukuda T, Kato R, et al. Comparable antileukemia/lymphoma effects in nonremission patients undergoing allogeneic hematopoietic cell transplantation with a conventional cytoreductive or reduced-intensity regimen. Biol Blood Marrow Transplant. 2007;13:932–941
  15. Hari P, Carreras J, Zhang MJ, et al. Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning. Biol Blood Marrow Transplant. 2008;14:236–245
  16. Shapira MY, Tsirigotis P, Resnick IB, et al. Allogeneic hematopoietic stem cell transplantation in the elderly. Crit Rev Oncol Hematol. 2007;64:49–63
  17. Barrett J, Childs R. Non-myeloablative stem cell transplants. Br J Haematol. 2000;111:6–17
  18. Anagnostopoulos A, Giralt S. Critical review on non-myeloablative stem cell transplantation (NST). Crit Rev Oncol Hematol. 2002;44:175–190
  19. Ruiz-Argulles GJ, Gomez-Almaguer D, Ruiz-ArguÌlles A, et al. Results of an outpatient-based stem cell allotransplant program using nonmyeloablative conditioning regimens. Am J Hematol. 2001;66:241–244
  20. Satwani P, Cooper N, Rao K, et al. Reduced intensity conditioning and allogeneic stem cell transplantation in childhood malignant and nonmalignant diseases. Bone Marrow Transplant. 2008;41:173–182
  21. Childs R, Chernoff A, Contentin N, et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med. 2000;343:750–758
  22. Adkins DR, DiPersio JF. Total body irradiation before an allogeneic stem cell transplantation: is there a magic dose?. Curr Opin Hematol. 2008;15:555–560
  23. Giralt S, Logan B, Rizzo D, et al. Reduced-intensity conditioning for unrelated donor progenitor cell transplantation: long-term follow-up of the first 285 reported to the National Marrow Donor Program. Biol Blood Marrow Transplant. 2007;13:844–852
  24. Anderlini P, Rizzo JD, Nugent ML, et al. Peripheral blood stem cell donation: an analysis from the International Bone Marrow Transplant Registry (IBMTR) and European Group for Blood and Marrow Transplant (EBMT) databases. Bone Marrow Transplant. 2001;27:689–692
  25. Sandmaier BM, Mackinnon S, Childs RW. Reduced intensity conditioning for allogeneic hematopoietic cell transplantation: current perspectives. Biol Blood Marrow Transplant. 2007;13:87–97
  26. Ings SJ, Balsa C, Leverett D, et al. Peripheral blood stem cell yield in 400 normal donors mobilised with granulocyte colony-stimulating factor (G-CSF): impact of age, sex, donor weight and type of G-CSF used. Br J Haematol. 2006;134:517–525
  27. Vasu S, Leitman SF, Tisdale JF, et al. Donor demographic and laboratory predictors of allogeneic peripheral blood stem cell mobilization in an ethnically diverse population. Blood. 2008;112:2092–2100
  28. Mehta J, Gordon LI, Tallman MS, et al. Does younger donor age affect the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies beneficially?. Bone Marrow Transplant. 2006;38:95–100
  29. Mielcarek M, Martin PJ, Leisenring W, et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood. 2003;102:756–762
  30. Subramaniam DS, Fowler DH, Pavletic SZ. Chronic graft-versus-host disease in the era of reduced-intensity conditioning. Leukemia. 2007;21:853–859
  31. Champlin R, Khouri I, Kornblau S, et al. Reinventing bone marrow transplantation: Reducing toxicity using nonmyeloablative, preparative regimens and induction of graft-versus-malignancy. Curr Opin Oncol. 1999;11:87–95
  32. Bolan CD, Childs RW, Procter JL, et al. Massive immune haemolysis after allogeneic peripheral blood stem cell transplantation with minor ABO incompatibility. Br J Haematol. 2001;112:787–795
  33. Resnick IB, Tsirigotis PD, Shapira MY, et al. ABO incompatibility is associated with increased non-relapse and GVHD related mortality in patients with malignancies treated with a reduced intensity regimen: a single center experience of 221 patients. Biol Blood Marrow Transplant. 2008;14:409–417
  34. Prieto JM, Atala J, Blanch J, et al. Psychometric study of quality of life instruments used during hospitalization for stem cell transplantation. J Psychosom Res. 2004;57:201–211
  35. Bevans MF, Mitchell SA, Marden S. The symptom experience in the first 100 days following allogeneic hematopoietic stem cell transplantation (HSCT). Support Care Cancer. 2008;16:1243–1254
  36. Giralt SA. Is reduced-intensity conditioning the standard of care in the transplant setting?. Clinical advances in hematology & oncology. 2008;6:337–339
  37. Sorror ML, Sandmaier BM, Storer BE, et al. Comorbidity and disease status-based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol. 2007;25:4246–4254
  38. Sorror ML, Storer BE, Maloney DG, et al. Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia. Blood. 2008;111:446–452
  39. Bolwell BJ. Are predictive factors clinically useful in bone marrow transplantation?. Bone Marrow Transplant. 2003;32:853–861
  40. Popplewell LL, Forman SJ. Is there an upper age limit for bone marrow transplantation?. Bone Marrow Transplant. 2002;29:277–284
  41. Robin M, Guardiola P, Dombret H, et al. Allogeneic bone marrow transplantation for acute myeloblastic leukaemia in remission: risk factors for long-term morbidity and mortality. Bone Marrow Transplant. 2003;31:877–887
  42. Alamo J, Shahjahan M, Lazarus HM, et al. Comorbidity indices in hematopoietic stem cell transplantation: a new report card. Bone Marrow Transplant. 2005;36:475–479
  43. Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912–2919
  44. Majhail NS, Brunstein CG, McAvoy S, et al. Does the hematopoietic cell transplantation specific comorbidity index predict transplant outcomes? A validation study in a large cohort of umbilical cord blood and matched related donor transplants. Biol Blood Marrow Transplant. 2008;14:985–992
  45. Sorror M, Storer B, Sandmaier BM, et al. Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation. Cancer. 2008;112:1992–2001
  46. Artz AS, Pollyea DA, Kocherginsky M, et al. Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2006;12:954–964
  47. Johnson JR, Temple R. Food and Drug Administration requirements for approval of new anticancer drugs. Cancer Treat Rep. 1985;69:115–1157
  48. Burke L. Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims. Washington, DC: US Department of Health and Human Services, Food and Drug Administration; 2006;
  49. National Institutes of Health. Patient-reported outcomes measurement information system. Washington, DC: National Institutes of Health; 2008;
  50. Hjermstad MJ, Holte H, Evensen SA, et al. Do patients who are treated with stem cell transplantation have a health-related quality of life comparable to the general population after 1 year?. Bone Marrow Transplant. 1999;24:911–918
  51. Lesko LM, Ostroff JS, Mumma GH, et al. Long-term psychological adjustment of acute leukemia survivors: impact of bone marrow transplantation versus conventional chemotherapy. Psychosom Med. 1992;54:30–47
  52. Goodwin JS, Hunt WC, Samet JM. A population-based study of functional status and social support networks of elderly patients newly diagnosed with cancer. Arch Intern Med. 1991;151:366–370
  53. Bevans MF, Marden S, Leidy NK, et al. Health-related quality of life in patients receiving reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2006;38:101–109
  54. Diez-Campelo M, Perez-Simon JA, Gonzalez-Porras JR, et al. Quality of life assessment in patients undergoing reduced intensity conditioning allogeneic as compared to autologous transplantation: results of a prospective study. Bone Marrow Transplant. 2004;34:729–738
  55. Andrykowski MA, Henslee PJ, Farrall MG. Physical and psychosocial functioning of adult survivors of allogeneic bone marrow transplantation. Bone Marrow Transplant. 1989;4:75–81
  56. McQuellon RP, Russell GB, Cella DF, et al. Quality of life measurement in bone marrow transplantation: development of the functional assessment of cancer therapy-bone marrow transplant (FACT-BMT) scale. Bone Marrow Transplant. 1997;19:357–368
  57. Baker F, Zabora J, Polland A, et al. Reintegration after bone marrow transplantation. Cancer Pract. 1999;7:190–197
  58. Foster LW, McLellan LJ, Rybicki LA, et al. Survival of patients who have undergone allogeneic bone marrow transplantation: the relative importance of in-hospital lay care-partner support. J Psychosoc Oncol. 2004;22:1–20
  59. Lee SJ, Klar N, Weeks JC, et al. Predicting costs of stem-cell transplantation. J Clin Oncol. 2000;18:64–71
  60. Saito AM, Cutler C, Zahrieh D, et al. Costs of allogeneic hematopoietic cell transplantation with high-dose regimens. Biol Blood Marrow Transplant. 2008;14:197–207
  61. Saito AM, Zahrieh D, Cutler C, et al. Lower costs associated with hematopoietic cell transplantation using reduced intensity vs high-dose regimens for hematological malignancy. Bone Marrow Transplant. 2007;40:209–217
  62. Cordonnier C, Maury S, Esperou H, et al. Do minitransplants have minicosts? A cost comparison between myeloablative and nonmyeloablative allogeneic stem cell transplant in patients with acute myeloid leukemia. Bone Marrow Transplant. 2005;36:649–654
  63. Gomez-Almaguer D, Ruiz-Arguelles GJ, Ruiz-Arguelles A, et al. Hematopoietic stem cell allografts using a non-myeloablative conditioning regimen can be safely performed on an outpatient basis: report of four cases. Bone Marrow Transplant. 2000;25:131–133
  64. Svahn BM, Remberger M, Myrback KE, et al. Home care during the pancytopenic phase after allogeneic hematopoietic stem cell transplantation is advantageous compared with hospital care. Blood. 2002;100:4317–4324
  65. Blank TO, Bellizzi KM. A gerontologic perspective on cancer and aging. Cancer. 2008;112:2569–2576

PII: S0749-2081(09)00025-4

doi: 10.1016/j.soncn.2009.03.006

Seminars in Oncology Nursing
Volume 25, Issue 2 , Pages 120-128 , May 2009

Article Tools